September 17th, 2020 

How Multispecific Drugs Are Transforming Amgen’s Pipeline

Host: Mikolaj Slabicki

Ray Deshaies

Prior to joining Amgen, Deshaies served as a professor at the California Institute of Technology (Caltech) and an executive officer in Caltech’s Division of Biology and Biological Engineering. He was also an investigator at the Howard Hughes Medical Institute. He has published over 150 papers on various subjects including discoveries of Sec61 translocon, cullin–RING ubiquitin ligases, and proteolysis-targeting chimeric molecules (Protacs).
In addition to his academic work, Deshaies co-founded Proteolix in 2003. In 2011, he co-founded Cleave Biosciences.
Deshaies holds a bachelor's degree in biochemistry from Cornell University and a Ph.D. in biochemistry from the University of California, Berkeley. He is also a member of the National Academy of Sciences, and American Academy of Arts and Sciences.

 

September 3rd, 2020 

Targeted degradation of extracellular proteins

Host: Katherine Donovan 

Carolyn Bertozzi is the Baker Family Director of Stanford ChEM-H and the Anne T. and Robert M. Bass Professor of Humanities and Sciences in the Department of Chemistry at Stanford University. She is also an Investigator of the Howard Hughes Medical Institute. Her research focuses on profiling changes in cell surface glycosylation associated with cancer, inflammation and infection, and exploiting this information for development of diagnostic and therapeutic approaches, most recently in the area of immuno-oncology. She is an elected member of the National Academy of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences. She also has been awarded the Lemelson-MIT Prize, a MacArthur Foundation Fellowship, the Chemistry for the Future Solvay Prize, among many others. 

Link to recorded seminar:

youtu.be/NTy9rWPUC3A

October 15th, 2020 

PROTACs:  The Past, Present and Future of Targeted Protein Degradation

Webinar registration:

https://dfci.zoom.us/webinar/register/WN_HWGMFH_NS_-qLfplWFifFg

Host: Radoslaw Nowak

Craig Crews

Craig Crews is the American Cancer Society and John Malone Professor of MCDB, Chemistry, and Pharmacology at Yale University.  For the past twenty years, his lab has pioneered the new field of ‘Targeted Protein Degradation’, i.e., PROTACs, as a novel therapeutic modality that has the potential to target currently ‘undruggable’ disease-causing proteins. In 2013, Dr. Crews founded the New Haven-based biotech venture, Arvinas, Inc., which is testing the first PROTAC-based drugs in clinical trials for prostate and breast cancer.  Dr. Crews has received numerous awards and honors, including the Ehrlich Award for Medicinal Chemistry (2014), the National Cancer Institute R35 Outstanding Investigator Award (2015), the AACR Award for Outstanding Achievement in Chemistry in Cancer Research (2017), the  Khorana Prize from the Royal Society of Chemistry( 2018), the  Pierre Fabre Award for Therapeutic Innovation (2018), and the Pharmacia-ASPET Award for Experimental Therapeutics (2019).

Previous Speakers

October 1st, 2020 

History and future of thalidomide analogs in human health

Host: Katherine Donovan 

Phil Chamberlain

Phil obtained his B.A. and D.Phil. degrees from the University of Oxford before traveling to the U.S. to work at the Genomics Institute of the Novartis Research Foundation (GNF). At GNF Phil supported and led projects in serious respiratory and inflammatory disease and solved multiple novel structures. Phil joined Celgene in 2007 and built and led the Structural and Chemical Biology department, most recently as Executive Director, Protein Homeostasis and Structural Biology. Phil was responsible for several fundamental scientific breakthroughs on the mechanism of action of thalidomide analogs, including the structural basis for cereblon recruitment and the definition of the neosubstrate ‘structural degron’. Phil led the construction of the cereblon modulator platform at Celgene, the pioneering drug discovery effort in the ‘molecular glue’ field. Phil has published work on targeted protein degradation in journals including Nature, Nature Structural and Molecular Biology and Nature Chemical Biology. Phil was the recipient of the John W. Jackson leadership award.